List of Moxeza drug patents

Moxeza is owned by Novartis.

Moxeza contains Moxifloxacin Hydrochloride.

Moxeza has a total of 2 drug patents out of which 0 drug patents have expired.

Moxeza was authorised for market use on 19 November, 2010.

Moxeza is available in solution/drops;ophthalmic dosage forms.

The generics of Moxeza are possible to be released after 29 May, 2029.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8450311 NOVARTIS Pharmaceutical compositions containing a fluoroquinolone antibiotic drug
May, 2029

(6 years from now)

US9114168 NOVARTIS Pharmaceutical compositions containing a fluoroquinolone antibiotic drug
May, 2029

(6 years from now)

Drugs and Companies using MOXIFLOXACIN HYDROCHLORIDE ingredient

Market Authorisation Date: 19 November, 2010

Treatment: NA

Dosage: SOLUTION/DROPS;OPHTHALMIC

How can I launch a generic of MOXEZA before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic